Globus Medical, Inc.
$96.1
▲
2.42%
2026-04-22 10:12:13
www.globusmedical.com
NYQ: GMED
Explore Globus Medical, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.01 B
Current Price
$96.1
52W High / Low
$101.4 / $51.79
Stock P/E
24.49
Book Value
$33.86
Dividend Yield
—
ROCE
11.18%
ROE
12.29%
Face Value
—
EPS
$3.92
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
6,000
Beta
1.09
Debt / Equity
2.61
Current Ratio
4.26
Quick Ratio
2.74
Forward P/E
18.24
Price / Sales
4.16
Enterprise Value
$11.79 B
EV / EBITDA
13.44
EV / Revenue
4.01
Rating
None
Target Price
$110.08
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Beta Bionics, Inc. | $12.91 | — | $576.08 M | — | -24.07% | -40.26% | $32.71 / $8.8 | $6.48 |
| 2. | Inogen, Inc. | $6.95 | — | $185.18 M | — | -12.85% | -12.43% | $9.13 / $5.34 | $7.06 |
| 3. | Envoy Medical, Inc. | $0.7 | — | $54.48 M | 3.34% | 741.34% | 155.22% | $1.91 / $0.36 | $-0.41 |
| 4. | Stryker Corporation | $334.05 | 39.78 | $127.84 B | 1.04% | 12.63% | 15.08% | $404.87 / $319.32 | $58.61 |
| 5. | Bio-Rad Laboratories, Inc. | NOT FOUND | — | — | — | 2.17% | 10.84% | $343.12 / $211.43 | $276.16 |
| 6. | Beyond Air, Inc. | $0.55 | — | $6.22 M | — | -177.71% | -2.4% | $5.84 / $0.43 | $0.96 |
| 7. | NovoCure Limited | $12.67 | — | $1.44 B | — | -26.47% | -38.89% | $20.06 / $9.82 | $3.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 826.42 M | 769.05 M | 745.34 M | 598.12 M | 657.29 M | — |
| Operating Profit | 181.31 M | 135.01 M | 122.81 M | 98.06 M | 77.06 M | — |
| Net Profit | 140.59 M | 118.97 M | 202.85 M | 75.46 M | 26.5 M | — |
| EPS in Rs | 1.04 | 0.88 | 1.5 | 0.56 | 0.2 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.94 B | 2.52 B | 1.57 B | 1.02 B |
| Operating Profit | 537.19 M | 219.39 M | 201.42 M | 236.25 M |
| Net Profit | 537.87 M | 102.98 M | 122.87 M | 190.17 M |
| EPS in Rs | 3.98 | 0.76 | 0.91 | 1.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.3 B | 5.25 B | 5.09 B | 2.08 B |
| Total Liabilities | 729.51 M | 1.07 B | 1.09 B | 229.75 M |
| Equity | 4.57 B | 4.18 B | 4 B | 1.85 B |
| Current Assets | 2.13 B | 2.18 B | 1.92 B | 983.34 M |
| Current Liabilities | 498.5 M | 855.91 M | 392.35 M | 159.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 753.45 M | 520.64 M | 243.5 M | 178.47 M |
| Investing CF | -355.01 M | -176.05 M | 302.97 M | -110.36 M |
| Financing CF | -679.16 M | -27.7 M | -231.82 M | -109.96 M |
| Free CF | 579.02 M | 405.21 M | 165.22 M | 104.42 M |
| Capex | -174.43 M | -115.43 M | -78.27 M | -74.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 60.62% | 53.34% | — | — |
| Earnings Growth % | -16.19% | -35.39% | — | — |
| Profit Margin % | 4.09% | 7.83% | 18.59% | — |
| Operating Margin % | 8.71% | 12.84% | 23.1% | — |
| Gross Margin % | 58.9% | 65.05% | 74.22% | — |
| EBITDA Margin % | 18.77% | 22.12% | 29.77% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.